Novartis' Troubles With Packaging Continue
Editor's ChoiceMain Category: Pharma Industry / Biotech Industry
Also Included In: Pharmacy / Pharmacist; Pain / Anesthetics
Article Date: 09 Jan 2012 - 12:00 PST
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
| Article Opinions: | 1 posts |
Novartis Consumer Health announced earlier today a recall on certain OTC medicines that were badly packaged and might have broken or chipped pills, as well as incorrect product mixed into bottles of pills. Rather worrying for consumers with risks of possible wrong or overdoses of their medicine.
Now the problems seem to be more endemic with the FDA inspection of the Novartis' Manufacturing facility finding other drugs that may have become mixed in the packing process.
It's rare for pharmaceutical manufacturers to have a problem of mixing up drugs, as the products are usually pressed into pills on a dedicated machine for that particular batch of the drug. It shouldn't really happen that different medications come anywhere near each other. Nonetheless, there appear to have been some fairly major procedural issues at the Novartis plant.
The products in the spotlight this time are opiate products made for Endo Pharmaceuticals by Novartis Consumer Health. The FDA is working closely with both companies to resolve the problems and prevent them occurring in the future.
The FDA is providing links on its website to help consumers and practitioners identify if there is a wrong pill in their medication. Patients and healthcare professionals would be wise follow the instructions on the links below closely, to identify whether there is a wrong pill in a medication bottle. Whilst the previous issue related to OTC products, these powerful oxymorphone and oxymorphone based painkillers could cause a patient serious issues if wrongly taken.
The problem relates to the following products :
- Opana® ER (oxymorphone hydrochloride) Extended-Release Tablets CII
- Opana® (oxymorphone hydrochloride) CII
- Oxymorphone hydrochloride Tablets CII
- PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets CII
- PERCODAN® (oxycodone hydrochloride and aspirin, USP) Tablets CII
- ENDOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets CII
- ENDODAN® (oxycodone hydrochloride and aspirin, USP) Tablets CII
- MORPHINE SULFATE Extended-Release Tablets CII
- ZYDONE® (hydrocodone bitartrate/acetaminophen tablets, USP) CIII
Visual Guide
Additional information is available from the FDA and Endo's website :
http://www.fda.gov/Drugs/DrugSafety/ucm286226.htm
http://www.fda.gov/Drugs/DrugSafety/ucm286232.htm
http://phx.corporate-ir.net/phoenix.zhtml?c=231492&p=irol-newsArticle&ID=1645894&highlight=
Written by Rupert Shepherd
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
23 Feb. 2012. <http://www.medicalnewstoday.com/articles/240080.php>
APA
http://www.medicalnewstoday.com/articles/240080.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Recall of OTC products by novartis
posted by Sharath on 14 Jan 2012 at 8:32 pmwhere actually the problem of recall took place, which plant of Novartis.this problem is an clear cut example of not following the cGMP.the ultimate sufferers are the consumers and patients,in count a great loss to the company reputation and money.so proper care must be taken before all this things happen. thank u
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



